Flavonols Boost Medication Absorption, Block Drug Resistance
Flavonols: Reshaping Drug Disposition and Overcoming Chemotherapy Resistance
Table of Contents
- Flavonols: Reshaping Drug Disposition and Overcoming Chemotherapy Resistance
Introduction
Dietary flavonols,naturally occurring compounds found in fruits,vegetables,and tea,are gaining attention for their potential to modulate drug behavior within the body. Emerging research suggests these compounds can inhibit a key transporter protein, Breast Cancer Resistance Protein (BCRP), impacting drug absorption, efficacy, and even reversing resistance to chemotherapy. This article explores the latest findings on flavonol-BCRP interactions, their implications for drug growth and clinical practice, and the crucial caveats to consider when translating these discoveries to human health.
Understanding BCRP and its role in Drug Resistance
Breast Cancer Resistance Protein (BCRP), also known as ABCG2, is a transmembrane transporter protein responsible for pumping a wide range of drugs out of cells. This efflux reduces the intracellular concentration of the drug, diminishing its effectiveness. BCRP is highly expressed in the intestinal lining,liver,and blood-brain barrier,influencing drug absorption,distribution,and elimination.In cancer cells, overexpression of BCRP is a major mechanism of chemotherapy resistance, rendering treatments ineffective.
Flavonols as BCRP Inhibitors: A Multi-pronged Approach
Recent investigations, published in Scientific Reports (Lee et al., 2025), demonstrate that several flavonols exhibit significant BCRP inhibitory activity. Researchers employed a comprehensive approach, combining in vitro (test tube), in silico (computer modeling), and in vain (in vivo, using animal models) experiments to assess these interactions.
In Vitro and In Silico Evidence
initial in vitro studies revealed that various flavonols effectively blocked BCRP function. Computational modeling (in silico) helped predict which flavonols would be most potent inhibitors, guiding the selection of compounds for further investigation. This combined approach accelerates the identification of promising candidates.
In Vivo Findings: Enhanced drug Exposure in Animal Models
crucially, the research extended beyond the lab dish. When administered to rats alongside SN-38, the active metabolite of the chemotherapy drug irinotecan, several flavonols reversed resistance to this drug. Specifically:
Quercetin increased SN-38 area under the curve (AUC) by approximately 188% (p less than 0.05) and Cmax to about 327 ng·h/mL (p less than 0.05) with modest Cmax elevation.
3,6,3′,4′-tetramethoxyflavone increased SN-38 Cmax to about 162 ng/mL (p less than 0.001) and AUClast to about 319 ng·h/mL (p less than 0.05), without altering the drug’s elimination rate.
These increases in drug exposure are attributed to BCRP inhibition in the intestine,leading to improved oral bioavailability – the fraction of the drug that reaches systemic circulation. This phenomenon has direct relevance to real-world drug-diet interactions, such as those observed with statins like rosuvastatin, and holds promise for improving chemotherapy outcomes where transporter overactivity limits drug efficacy.
Beyond Chemotherapy: Implications for Drug Bioavailability
The ability of flavonols to inhibit BCRP extends beyond cancer treatment. Many drugs suffer from poor oral bioavailability due to BCRP-mediated efflux. By blocking BCRP, flavonols could potentially enhance the absorption and effectiveness of these medications. This opens avenues for improving therapies across a wide range of conditions.
A Word of Caution: Bioavailability, Species Differences, and Clinical Translation
Despite the encouraging findings, several significant limitations must be considered. The plasma concentrations of the flavonols themselves were surprisingly low after oral administration to rats, suggesting their primary impact may be localized to the intestinal tract. This raises questions about their ability to overcome drug resistance in cancers outside the gastrointestinal system unless their systemic bioavailability can be improved.
Moreover, significant differences exist between human and rat BCRP transporters, and BCRP expression levels vary across tissues and species. Thus, direct extrapolation of these results to humans requires caution. It’s vital to remember that preclinical models,while valuable for understanding mechanisms,do not guarantee efficacy or safety in human patients.
Pharmacokinetic Considerations
The study meticulously quantified plasma levels using Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) with Electrospray ionization (ESI+) and Multiple Reaction monitoring (MRM), employing an internal standard (IS).This allowed for the calculation of key pharmacokinetic parameters – AUCl